|
🐜
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
35 auth.
J. Smolen,
R. Landewé,
F. Breedveld,
M. Dougados,
P. Emery,
C. Gaujoux-Viala,
S. Gorter,
R. Knevel,
J. Nam,
M. Schoels,
D. Aletaha,
M. Buch,
L. Gossec,
T. Huizinga,
J. Bijlsma,
...
G. Burmester,
B. Combe,
M. Cutolo,
C. Gabay,
J. Gómez-Reino,
M. Kouloumas,
T. Kvien,
E. Martı́n-Mola,
I. McInnes,
K. Pavelka,
P. V. van Riel,
Marieke Scholte,
D. Scott,
T. Sokka,
G. Valesini,
R. V. van Vollenhoven,
K. Winthrop,
J. Wong,
A. Zink,
D. M. van der Heijde
|
11 |
2010 |
11
🐜
|
|
🐜
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
49 auth.
J. Smolen,
R. Landewé,
J. Bijlsma,
G. Burmester,
K. Chatzidionysiou,
M. Dougados,
J. Nam,
S. Ramiro,
M. Voshaar,
R. V. van Vollenhoven,
D. Aletaha,
M. Aringer,
M. Boers,
C. Buckley,
F. Buttgereit,
...
V. Bykerk,
M. Cardiel,
B. Combe,
M. Cutolo,
Y. van Eijk-Hustings,
P. Emery,
A. Finckh,
C. Gabay,
J. Gómez-Reino,
L. Gossec,
J. Gottenberg,
J. Hazes,
T. Huizinga,
M. Jani,
D. Karateev,
M. Kouloumas,
T. Kvien,
Zhanguo Li,
X. Mariette,
I. McInnes,
E. Mysler,
P. Nash,
K. Pavelka,
G. Poór,
C. Richez,
P. V. van Riel,
A. Rubbert-Roth,
K. Saag,
J. D. da Silva,
T. Stamm,
T. Takeuchi,
R. Westhovens,
M. D. de Wit,
D. M. van der Heijde
|
11 |
2010 |
11
🐜
|
|
🐜
|
Genetics of rheumatoid arthritis contributes to biology and drug discovery
95 auth.
Y. Okada,
Di Wu,
G. Trynka,
T. Raj,
C. Terao,
K. Ikari,
Y. Kochi,
K. Ohmura,
A. Suzuki,
S. Yoshida,
R. Graham,
A. Manoharan,
W. Ortmann,
T. Bhangale,
J. Denny,
...
R. Carroll,
A. Eyler,
J. Greenberg,
J. Kremer,
D. Pappas,
Lei Jiang,
Jian Yin,
Lingying Ye,
D. Su,
Jian Yang,
G. Xie,
E. Keystone,
H. Westra,
T. Esko,
A. Metspalu,
Xuezhong Zhou,
N. Gupta,
D. Mirel,
E. Stahl,
D. Diogo,
J. Cui,
K. Liao,
Michael H. Guo,
K. Myouzen,
T. Kawaguchi,
M. Coenen,
P. V. van Riel,
M. A. van de Laar,
H. Guchelaar,
T. Huizinga,
P. Dieudé,
X. Mariette,
S. L. Bridges,
A. Zhernakova,
R. Toes,
P. Tak,
C. Miceli-Richard,
S. Bang,
Hye-Soon Lee,
Javier Martín,
M. González-Gay,
L. Rodríguez-Rodríguez,
S. Rantapää-Dahlqvist,
L. Ärlestig,
Hyon K. Choi,
Y. Kamatani,
P. Galan,
M. Lathrop,
S. Eyre,
J. Bowes,
A. Barton,
N. de Vries,
L. Moreland,
L. Criswell,
E. Karlson,
A. Taniguchi,
R. Yamada,
M. Kubo,
Jun S. Liu,
S. Bae,
Jane Worthington,
L. Padyukov,
L. Klareskog,
P. Gregersen,
S. Raychaudhuri,
B. Stranger,
P. D. De Jager,
L. Franke,
P. Visscher,
M. Brown,
H. Yamanaka,
T. Mimori,
A. Takahashi,
Huji Xu,
T. Behrens,
K. Siminovitch,
S. Momohara,
F. Matsuda,
Kazuhiko Yamamoto,
R. Plenge
|
10 |
2013 |
10
🐜
|
|
🐜
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
33 auth.
J. Smolen,
R. Landewé,
F. Breedveld,
M. Buch,
G. Burmester,
M. Dougados,
P. Emery,
C. Gaujoux-Viala,
L. Gossec,
J. Nam,
S. Ramiro,
K. Winthrop,
M. D. de Wit,
D. Aletaha,
N. Betteridge,
...
J. Bijlsma,
M. Boers,
F. Buttgereit,
B. Combe,
M. Cutolo,
N. Damjanov,
J. Hazes,
M. Kouloumas,
T. Kvien,
X. Mariette,
K. Pavelka,
P. V. van Riel,
A. Rubbert-Roth,
M. Scholte-Voshaar,
D. Scott,
T. Sokka-Isler,
J. Wong,
D. M. van der Heijde
|
10 |
2013 |
10
🐜
|
|
🐬
|
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
C. Popa,
M. Netea,
P. V. van Riel,
J. V. D. van der Meer,
A. Stalenhoef
|
9 |
2007 |
9
🐬
|
|
🐬
|
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis
R. Laan,
P. V. van Riel,
L. V. D. van de Putte,
L. van Erning,
M. V. van’t Hof,
J. Lemmens
|
8 |
1993 |
8
🐬
|
|
🐜
|
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.
45 auth.
L. van Bon,
A. Affandi,
J. Broen,
R. Christmann,
R. Marijnissen,
L. Stawski,
G. Farina,
Giuseppina Stifano,
Allison L. Mathes,
M. Cossu,
M. York,
C. Collins,
M. Wenink,
R. Huijbens,
R. Hesselstrand,
...
T. Saxne,
Michael Dimarzio,
D. Wuttge,
S. Agarwal,
J. Reveille,
S. Assassi,
M. Mayes,
Yanhui Deng,
J. Drenth,
J. de Graaf,
M. den Heijer,
C. Kallenberg,
M. Bijl,
A. Loof,
W. B. van den Berg,
L. Joosten,
V. Smith,
F. de Keyser,
R. Scorza,
C. Lunardi,
P. V. van Riel,
M. Vonk,
W. V. van Heerde,
S. Meller,
B. Homey,
L. Beretta,
M. Roest,
M. Trojanowska,
R. Lafyatis,
T. Radstake
|
8 |
2014 |
8
🐜
|
|
🐜
|
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
9 auth.
C. Gaujoux-Viala,
J. Smolen,
R. Landewé,
M. Dougados,
T. Kvien,
E. Mola,
...
M. Scholte-Voshaar,
P. V. van Riel,
L. Gossec
|
8 |
2010 |
8
🐜
|
|
🐜
|
Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma.
8 auth.
T. Radstake,
M. Roelofs,
Y. Jenniskens,
Birgitte Oppers-Walgreen,
P. V. van Riel,
P. Barrera,
...
L. Joosten,
W. B. van den Berg
|
8 |
2004 |
8
🐜
|
|
🐜
|
EULAR definition of difficult-to-treat rheumatoid arthritis
31 auth.
G. Nagy,
N. Roodenrijs,
P. Welsing,
M. Kedves,
A. Hamar,
M. C. van der Goes,
A. Kent,
M. Bakkers,
E. Blaas,
L. Šenolt,
Z. Szekanecz,
E. Choy,
M. Dougados,
J. Jacobs,
R. Geenen,
...
H. Bijlsma,
A. Zink,
D. Aletaha,
L. Schoneveld,
P. V. van Riel,
L. Gutermann,
Yeliz Prior,
E. Nikiphorou,
G. Ferraccioli,
G. Schett,
K. Hyrich,
U. Mueller-Ladner,
M. Buch,
I. McInnes,
D. M. van der Heijde,
J. V. van Laar
|
8 |
2020 |
8
🐜
|
|
🐢
|
Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study
M. Flendrie,
W. Vissers,
M. Creemers,
E. D. De Jong,
P. C. van de Kerkhof,
P. V. van Riel
|
8 |
2005 |
8
🐢
|
|
🐜
|
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.
8 auth.
P. Welsing,
R. Landewé,
P. V. van Riel,
M. Boers,
Anke M van Gestel,
S. van der Linden,
...
Hilde Swinkels,
D. M. van der Heijde
|
8 |
2004 |
8
🐜
|
|
🐜
|
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
14 auth.
K. Chatzidionysiou,
E. Lie,
E. Nasonov,
G. Lukina,
M. Hetland,
U. Tarp,
C. Gabay,
P. V. van Riel,
D. Nordström,
J. Gómez-Reino,
...
K. Pavelka,
M. Tomšič,
T. Kvien,
R. V. van Vollenhoven
|
7 |
2011 |
7
🐜
|
